Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00627354
What this trial is testing

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
Groupe D'Etude des Tumeurs Uro-Genitales 90
Large-scale testing (Phase 3)Study completedNCT01057810
What this trial is testing

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb 837
Testing effectiveness (Phase 2)Looking for participantsNCT04104776
What this trial is testing

Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Who this might be right for
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more
Novartis Pharmaceuticals 300
Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Testing effectiveness (Phase 2)Study completedNCT00667862
What this trial is testing

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 35
Early research (Phase 1)Ended earlyNCT00511576
What this trial is testing

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Who this might be right for
Breast CancerLung CancerPulmonary Cancer+5 more
Mirati Therapeutics Inc. 54
Testing effectiveness (Phase 2)Ended earlyNCT02656615
What this trial is testing

Abiraterone-Rechallenge Study for CRPC Patients

Who this might be right for
Prostate Cancer
Aurelius Omlin 4
Early research (Phase 1)Study completedNCT03517488
What this trial is testing

XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Who this might be right for
MelanomaBreast CarcinomaHepatocellular Carcinoma+25 more
Xencor, Inc. 150
Testing effectiveness (Phase 2)Temporarily pausedNCT06200103
What this trial is testing

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic 236
Testing effectiveness (Phase 2)Ended earlyNCT02203513
What this trial is testing

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Ovarian CancerBreast CancerProstate Cancer
National Cancer Institute (NCI) 111
Early research (Phase 1)Study completedNCT00005627
What this trial is testing

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06039371
What this trial is testing

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
University of Washington 69
Testing effectiveness (Phase 2)Ended earlyNCT00176631
What this trial is testing

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
Rutgers, The State University of New Jersey 10
Testing effectiveness (Phase 2)Study completedNCT00246753
What this trial is testing

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
UNC Lineberger Comprehensive Cancer Center 29
Testing effectiveness (Phase 2)UnknownNCT01630967
What this trial is testing

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Neoplasm
British Columbia Cancer Agency 40
Testing effectiveness (Phase 2)Ended earlyNCT01703065
What this trial is testing

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateCastration-resistant Prostate CancerRecurrent Prostate Cancer+2 more
University of Washington 9
Testing effectiveness (Phase 2)Study completedNCT01331083
What this trial is testing

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 68
Not applicableUnknownNCT05612841
What this trial is testing

A Study on Drug-drug Interactions in Patients Treated With Anticancer Agents for a Prostate Cancer in Real Life Setting

Who this might be right for
Prostatic Neoplasm
Centre Hospitalier Universitaire de Besancon 264
Testing effectiveness (Phase 2)Study completedNCT02105675
What this trial is testing

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerProstate Cancer Metastatic
SOTIO a.s. 60
Testing effectiveness (Phase 2)Study completedNCT02787005
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC 388
Next Page